351990-69-7 Usage
Uses
Used in Pharmaceutical Research and Development:
3-amino-4-chloro-1H-pyrazole-5-carboxylic acid (SALTDATA: FREE) is utilized as a key intermediate in the synthesis of new drugs, particularly for the development of pharmaceuticals with novel therapeutic properties. Its unique structure allows for the creation of more complex organic molecules, which can be further explored for their potential medicinal applications.
Used in Organic Synthesis:
In the field of organic chemistry, 3-amino-4-chloro-1H-pyrazole-5-carboxylic acid (SALTDATA: FREE) serves as a building block for the synthesis of more complex organic molecules. Its versatile functional groups enable chemists to modify and extend its structure, leading to the discovery of new compounds with potential applications in various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 351990-69-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,5,1,9,9 and 0 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 351990-69:
(8*3)+(7*5)+(6*1)+(5*9)+(4*9)+(3*0)+(2*6)+(1*9)=167
167 % 10 = 7
So 351990-69-7 is a valid CAS Registry Number.
InChI:InChI=1S/C4H4ClN3O2/c5-1-2(4(9)10)7-8-3(1)6/h(H,9,10)(H3,6,7,8)
351990-69-7Relevant articles and documents
Nitropyrazoles : 118. Synthesis and transformations of 5-amino-3,4- dinitropyrazole
Dalinger,Vatsadse,Shkineva,Popova,Ugrak,Shevelev
experimental part, p. 1631 - 1638 (2011/05/03)
A method of preparation of 5-amino-3,4-dinitropyrazole (1) from 3(5)-methyl-5(3)-nitro- and 3(5)-methyl-4,5(3)-dinitropyrazoles was developed, the key step of which was the Hofmann rearrengement of nitro- and dinitropyrazolecarboxamides. The protonation o
COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROL OF HEPATITIS C VIRAL INFECTIONS
-
Page/Page column 55, (2010/09/17)
Various tetrahydropyrazolo[1,5-a]pyrimidine compounds, compositions, methods of making, and methods for the prevention and treatment of HCV infections and associated diseases are disclosed. The invention further relates to biomarkers for identification of HCV strains which are resistant to the tetrahydropyrazolo[1,5- a]pyrimidine compounds.
